Single domain protein scaffold8/6/2023 ![]() Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, Vanhove C, Revets H, De Baetselier P, Lahoutte T (2008) Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. ![]() 35:2245–2255Įngfeldt T, Renberg B, Brumer H, Nygren PA, Karlström AE (2005) Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein. Oncol Rep 8:387–392Įkblad T, Tran T, Orlova A, Widström C, Feldwisch J, Abrahmsén L, Wennborg A, Karlström AE, Tolmachev V (2008) Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Curr Radiopharm 1:37–41ĭi Carlo A, Mariano A, D’Alessandro V, Belli G, Romano G, Macchia V (2001) Evaluation of epidermal growth factor receptor, carcinoembryonic antigen and Lewis carbohydrate antigens in human colorectal and liver neoplasias. Mol Imaging Biol (Epub ahead of print)Ĭortez-Retamozo V, Lahoutte T, Caveliers V, Gainkam LO, Hernot S, Packeu A, De Vos F, Vanhove C, Muyldermans S, Baetselier PD, Revets H (2008) 99mTc-labeled nanobodies: a new type of targeted probes for imaging antigen expression. J Nucl Med 49:804–813Ĭheng Z, De Jesus OP, Kramer DJ, De A, Webster JM, Gheysens O, Levi J, Namavari M, Wang S, Park JM, Zhang R, Liu H, Lee B, Syud FA, Gambhir SS (2009) 64Cu-labeled Affibody molecules for imaging of HER2 expressing tumors. J Mol Biol 382:779–789Ĭheng Z, Padilla De Jesus O, Namavari M, De A, Levi J, Webster JM, Zhang R, Lee B, Syud FA, Gambhirl SS (2008) Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. Nat Biotechnol 22:575–582Ĭhen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS (2008) Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Nucl Med 47(suppl):108Pīinz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, Grutter MG, Plückthun A (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. ChemBioChem 10:2663–2670īaum RP, Orlova A, Tolmachev V, Feldwisch J (2006) Receptor PET/CT and SPECT using an Affibody molecule for targeting and molecular imaging of HER2-positive cancer in animal xenografts and human breast cancer patients. FEBS Lett 414:521–526Īustin J, Wang W, Puttamadappa S, Shekhtman A, Camarero JA (2009) Biosynthesis and biological screening of a genetically encoded library based on the cyclotide MCoTI-I. ![]() J Biol Chem 280:24715–24722Īrbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. J Nucl Med 50:781–789Īmstutz P, Binz HK, Parizek P, Stumpp MT, Kohl A, Grutter MG, Forrer P, Plückthun A (2005) Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. Bioconjug Chem 19:235–243Īhlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V (2009) Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, Z HER2:2395, with C-terminally engineered cysteine. The success of those molecular probes demonstrates the adequacy of protein scaffold strategy as a general approach in molecular probe development.Īhlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, Widmark O, Fant G, Feldwisch J, Tolmachev V (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. High tumor contrast imaging has been obtained within 1 h after injection. Quantitative data obtained from positron emission tomography, single photon emission computed tomography/CT, and optical imaging together with biodistribution studies have shown high tumor uptakes and high tumor-to-blood ratios for these probes. Among the evaluated probes Affibody molecules and analogs, cystine knot peptides, and nanobodies have shown especially good characteristics as protein scaffold platforms for development of in vivo molecular probes. For the purpose of development of new generation molecular probes, various protein scaffold molecules have been labeled with imaging moieties and evaluated both in vitro and in vivo. They belong to the peptide and small protein platform with distinct properties. Protein scaffold molecules are powerful reagents for targeting various cell signal receptors, enzymes, cytokines and other cancer-related molecules.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |